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Abstract
Background—Systemic modulation of Group I and II metabotropic glutamate receptors (mGluRs)
regulate ethanol self-administration in a variety of animal models. Although these receptors are
expressed in reward-related brain regions, the anatomical specificity of their functional involvement
in ethanol self-administration remains to be characterized. This study sought to evaluate the
functional role of Group I (mGluR5) and Group II (mGluR2/3) in mesocorticolimbic brain regions
in ethanol self-administration.
Methods—Alcohol-preferring (P) rats, a genetic model of high alcohol drinking, were trained to
self-administer ethanol (15% v/v) versus water in operant conditioning chambers. Effects of brain
site-specific infusion of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine hydrochloride
(MPEP) and the mGluR2/3 agonist were then assessed on the maintenance of self-administration.
Results—Microinjection of the mGluR5 antagonist MPEP in the nucleus accumbens reduced
ethanol self-administration at a dose that did not alter locomotor activity. By contrast, infusion of
the mGluR2/3 agonist LY379268 in the nucleus accumbens reduced self-administration and
produced nonspecific reductions in locomotor activity. The mGluR5 involvement showed anatomical
specificity as evidenced by lack of effect of MPEP infusion in the dorsomedial caudate or medial
prefrontal cortex on ethanol self-administration. To determine reinforcer specificity, P-rats were
trained to self-administer sucrose (.4% w/v) versus water, and effects of intra-accumbens MPEP were
tested. The MPEP did not alter sucrose self-administration or motor behavior.
Conclusions—These results suggest that mGluR5 activity specifically in the nucleus accumbens
is required for the maintenance of ethanol self-administration in individuals with genetic risk for high
alcohol consumption.
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The amino acid glutamate is the primary excitatory transmitter in the mammalian brain. Fast
excitatory actions of glutamate are mediated by ionotropic N-methyl-D-aspartate (NMDA),
α-amino-3-hydroxi-5-methyl-ioxyzole-4-propionic acid (AMPA), and kainite (KA) receptors.
Metabotropic glutamate receptors (mGluRs) mediate slower glutamate responses through G-
protein coupling to various intracellular signaling cascades that can modulate ionotropic
receptor function (1). In addition to its well-known effects on ionotropic glutamate receptor
function (2–9), ethanol modulates general metabotropic receptor activity as evidenced by
reduced basal and stimulated phosphoinositide hydrolysis (10).
The mGluRs comprise eight subtypes categorized into three groups according to similar
properties, such as sequence homology, molecular structure, selective pathways of signal
transduction, and pharmacological profiles (11–13). Group I receptors (mGluR1 and mGluR5)
are coupled to Gq, stimulate phospholipase C and phosphoinositide hydrolysis (14,15), are
predominantly located postsynaptically, and modulate neuronal signaling and cellular
excitability (16). The Group II (mGluR2 and 3) and Group III (mGluR4, 6, 7, and 8) family of
receptors couple to Gi, a pathway that inhibits cyclic adenosine monophosphate formation upon
activation (16,17), and are predominantly located presynaptically but have also been localized
postsynaptically (18) and function to regulate glutamate release to appropriate physiological
levels (17). The mGluRs regulate a variety of neurobiological processes, such as learning and
memory, synaptic plasticity, and modulation of ionotropic glutamate and γ-aminobutyric acid
(GABA) receptor activity, as well as facilitating glutamate release (16,19–22). Low
concentrations of ethanol selectively alter neuronal firing rates (23) and Ca2+ levels (24)
mediated by mGluRs in vitro, which suggests that ethanol has direct actions on mGluR activity.
Although the neurobiological substrates that regulate the positive reinforcing effects of ethanol
remain to be fully characterized, the mesolimbic system has received considerable attention
because of its general involvement in reinforcement (25–28) and drug self-administration
(29–32). Early studies focused on dopamine neurotransmission within this system, because
acute injection of ethanol was found to increase extracellular dopamine levels in the nucleus
accumbens (33). Infusion of dopamine agonists in the nucleus accumbens increases ethanol-
reinforced responding, whereas D1 and D2 receptor antagonists produce decreases (29,34,
35). Similarly, microinjection studies have shown that intra-accumbens systems that interact
with dopamine—including GABA-A (36,37), opiate (38,39), and endocannabinoid CB1 (40)
receptors—regulate ethanol reinforcement. Evidence also shows that ethanol injection
increases glutamate levels in the nucleus accumbens (41) and NMDA receptor antagonist
infusion in the nucleus accumbens decreases ethanol-reinforced responding (42,43), which
underscores the potential importance of mesolimbic glutamate in this process.
Group I and II mGluRs are highly expressed in the mesocorticolimbic system. mGluR5s and
mGluR2/3s are abundant in regions such as the nucleus accumbens, lateral septum, striatum,
amygdala, and hippocampus (15,44–46). Alternatively, mGluR1s show low expression in most
limbic brain regions but are highly expressed in the cerebellum where they regulate motor
coordination (47). This differential mesocorticolimbic distribution pattern of mGluR subtypes
suggests that mGluR5 and mGluR2/3 might regulate ethanol reinforcement, but mGluR1 might
not. Indeed, systemically administered mGluR5 antagonists and mGluR2/3 agonists have been
shown to modulate cocaine, nicotine, and ethanol reinforcement and drug-seeking behavior in
reinstatement models (48–55). By contrast, mGluR1 receptor modulation of ethanol self-
administration is attributable to nonspecific motor impairment (56,57). Furthermore, evidence
from site-specific infusion studies shows that ethanol self-administration is modulated by
activity of specific brain regions, including the nucleus accumbens and frontal cortex (29,35,
36,42,58), that express high levels of mGluR5 and mGluR2/3. Accordingly, the present study
was designed to examine the direct functional involvement of mGluR5 or mGluR2/3 expressed
in mesocorticolimbic brain regions in ethanol reinforcement.
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Because individuals with variation in the mGluR5 gene (GRM5) show significant risk for
developing alcohol dependence (59), we sought to examine the functional involvement of
mesocorticolimbic mGluR5 and mGluR2/3 in ethanol reinforcement in alcohol-preferring (P)
rats, a prominent genetic model of high alcohol intake (60). The P-rat line has been found to
fulfill the requirements of an animal model of alcoholism (61), because these rats voluntarily
consume alcohol in quantities that produce significant blood alcohol concentrations, develop
tolerance and dependence through voluntary drinking (62–64), and maintain preference for
ethanol when palatable solutions are presented as an alternative (65). Briefly, P-rats were
trained to self-administer ethanol (15% v/v) and then received surgical implantation of bilateral
injector cannulae aimed at the nucleus accumbens core; however, no attempt was made to
differentiate between subnuclei of the accumbens (e.g., core vs. shell), because the extent of
drug diffusion is greater than the anatomical distance between these structures (66). After
surgery, effects of intra-accumbens infusion of the mGluR5 antagonist 2-methyl-6-
(phenylethynyl)pyridine hydrochloride (MPEP) and the mGluR2/3 agonist (1R,4R,5S,6R)-4-
amino-2-oxabicyclo(3.1.0)hexane-4,6-dicarboxylic acid (LY379268) on the maintenance of
ethanol self-administration were determined. The mGluR5 antagonist was also tested in the
dorsomedial striatum and medial prefrontal cortex (mPFC) to further examine anatomical
specificity of mGluR5 involvement in ethanol-reinforced responding. To assess reinforcer
specificity, the mGluR5 antagonist was administered in the nucleus accumbens of P-rats trained
to self-administer sucrose (.4% w/v) versus water. Finally, locomotor assessments were
conducted after site-specific infusion of mGluR5 or mGluR2/3 compounds to determine
whether reductions in self-administration were associated with nonspecific motor impairments.
Methods and Materials
See Supplement 1 for detailed methods.
Procedure
Ethanol Self-Administration Training
Male ethanol-preferring rats were trained to self-administer ethanol (15% v/v) versus water
during daily (Monday–Friday) 30-min sessions in operant conditioning chambers with a
sucrose-fading procedure (67) as previously described (36,50,57,68). After sucrose fading,
self-administration sessions with ethanol (15% v/v) and water as the reinforcers continued for
the remainder of the study. After completion of 28 baseline self-administration sessions with
15% ethanol, rats underwent surgery for cannulae implantation
Testing of mGluR Compounds in the Nucleus Accumbens on Ethanol Self-Administration
Rats were habituated to the microinjection procedure by receiving a sham infusion as the initial
test. For testing of the mGlu receptor compounds, rats received a bilateral microinjection of a
single MPEP (0 μg, 1 μg, 3 μg, 10 μg; n = 6) or LY379268 (0 μg, .03 μg, .1 μg, .17 μg; n = 9)
dose in randomized order. After injectors were removed, rats were placed in the chambers for
a self-administration session (30 min). Test sessions were interspersed with training sessions
with at least two self-administration sessions between tests. The MPEP and LY379268 dose
order was randomized.
Testing of mGluR Compounds in the Nucleus Accumbens on Locomotor Activity
After the mGlu receptor compound evaluation on ethanol self-administration, the lowest
effective dose of MPEP and LY379268 that reduced ethanol self-administration was evaluated
to determine whether the reductions in ethanol self-administration were accompanied by motor
impairments. Rats were administered the same mGluR compound tested in self-administration,
either MPEP (0 μg, 10 μg) or LY379268 (0 μg, .17 μg), and immediately placed in the activity
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chambers for 30-min sessions. Dose order was randomly assigned, and each rat experienced
two locomotor sessions. Locomotor sessions were interspersed with self-administration
sessions with at least 3 days between tests. Self-administration sessions were withheld on the
days of the locomotor assessments.
Testing of mGluR5 Antagonist in the Dorsomedial Caudate Putamen and mPFC on Ethanol
Self-Administration and Locomotor Activity
Rats received implantation of bilateral cannulae aimed at the dorsomedial caudate putamen
(n = 9) or the mPFC (n = 7). Rats were habituated to the microinjection procedure and then
administered MPEP (0 μg, 1 μg, 3 μg, 10 μg; dorsomedial caudate) or MPEP (0 μg, 1 μg, 3
μg, 10 μg, 30 μg; mPFC) in random dose order with at least two baseline sessions between
tests. After the self-administration assessment, effects of MPEP (dorsomedial caudate: 0 μg,
10 μg; mPFC: 0 μg, 30 μg) were tested on motor activity with the same procedure as previously
described.
Testing of mGluR5 Antagonist in the Nucleus Accumbens on Sucrose Self-Administration
and Locomotor Activity
Rats were trained to self-administer sucrose (.4% w/v) versus water with procedures as
described for ethanol self-administration with the exception that ethanol was never present in
the solution. This concentration of sucrose was chosen because we have previously shown that
this dose results in similar baseline responding as 15% v/v ethanol (56,57). After 22 baseline
sessions, rats received implantation of bilateral cannulae aimed at the nucleus accumbens.
Effects of presession administration of MPEP (0 μg, 1 μg, 3 μg, 10 μg, 30 μg; n = 8) in nucleus
accumbens was then evaluated on sucrose self-administration as described for ethanol. After
the self-administration assessment, effects of MPEP (0 μg, 30 μg) were tested on motor activity
with the same procedure as previously described.
Drugs
Ethanol (95%) was diluted in distilled water. The MPEP (Sigma Aldrich, St. Louis, Missouri),
a selective antagonist of mGluR5 (69), and LY379268 (Tocris, Ellisville, Missouri), a selective
Group II (mGluR2/3) agonist (70), were dissolved in artificial cerebrospinal fluid (aCSF).
Data Analysis
Total responses on the ethanol (or sucrose) and water levers and ethanol intake (g/kg) were
analyzed by a one-way repeated measures analysis of variance (RM ANOVA) with Dunnett
post hoc analyses. Cumulative ethanol responses and locomotor activity during the 30-min
sessions were analyzed with a two-way RM ANOVA with Tukey post hoc comparisons to
extract significant main effects and interactions. Statistical significance was declared at p ≤ .
05.
Results
Testing of mGluR Compounds in the Nucleus Accumbens on Ethanol Self-Administration
and Motor Activity
Average baseline data (mean ± SEM) for the 2 days preceding the sham test of MPEP and
LY379268 on ethanol self-administration are shown in Table 1. Histological verification
showed that injection sites were in the nucleus accumbens core (Figures 1A and 1B). Intra-
accumbens infusion of the mGluR5 antagonist MPEP significantly reduced total session
ethanol (15% v/v) responding [F(3,15) = 4.65, p < .02] (Figure 2A). No MPEP-induced changes
in water responses were evident. Ethanol intake (g/kg) was also significantly reduced by MPEP
Besheer et al. Page 4













[F(3,15) = 4.65, p = .02], with significantly reduced ethanol intake at the highest MPEP dose
(10 μg; Table 2). Cumulative ethanol responses were examined to determine the pattern of
ethanol responding across the 30-min session (Figure 2B). The two-way RM ANOVA showed
a significant main effect of time [F(5,25) = 45.25, p < .001], a significant main effect of MPEP
dose [F(3,15) = 4.97, p < .01], and a significant interaction [F(15,75) = 1.88, p < .04], with a
significant MPEP (10 μg)-induced reduction in ethanol-reinforced responding during the last
half of the session (p values < .03). In the locomotor assessment, the dose of MPEP (10 μg)
that reduced ethanol-reinforced responding did not alter activity across the 30-min session
(Figure 2C). The two-way RM ANOVA showed a significant increase in activity over time
[F(14,56) = 28.81, p < .001], with no significant main effect of MPEP dose or dose × time
interaction.
Intra-accumbens administration of the mGluR2/3 agonist LY379268 also significantly reduced
total session ethanol responses [F(3,17) = 3.76, p = .03] (Figure 2D) and ethanol intake [F
(3,17) = 4.19, p = .02] (Table 2). Water responses were unchanged by LY379268 pretreatment.
As shown in Figure 2E, analysis of the cumulative ethanol responses showed a significant main
effect of time [F(5,25) = 12.90, p < .001] and a significant interaction [F(15,75) = 2.99, p < .
001], with reduced ethanol responding relative to vehicle during the last half of the session
(p values ≤ .02) after treatment with the highest LY379268 dose (.17 μg). The dose of
LY379268 (.17 μg) that decreased ethanol-reinforced responding produced a significant
reduction in locomotor activity, because examination of the cumulative distance traveled across
the 30-min session showed a significant main effect of LY379268 dose [F(1,5) = 8.42, p = .
03], a significant main effect of time [F(14,70) = 46.10, p < .001], and a significant LY379268
dose × time interaction [F(14,70) = 5.21, p < .001] (Figure 2F). The LY379268-induced
reduction in cumulative distance emerged at min 12 and continued throughout the session (p
values ≤ .04).
Testing of mGluR5 Antagonist in the Dorsomedial Caudate Putamen and the mPFC on
Ethanol Self-Administration and Motor Activity
Average baseline data (mean ± SEM) for both the dorsomedial caudate and mPFC group for
the 2 days preceding the sham infusion are shown in Table 1. Dorsomedial caudate
administration (Figures 1C and 1D) of MPEP did not alter ethanol (15% v/v) self-
administration (Figure 3A) or ethanol intake (g/kg; Table 2). Analysis of cumulative ethanol
responses across the 30-min session indicated a significant main effect of time [F(5,25) = 29.27,
p < .001] but no main effect of MPEP dose or interaction (Figure 3B). Interestingly,
intracaudate MPEP induced a significant increase in total session water responding (Table 3)
at the highest MPEP dose [10 μg; F(3,17) = 3.28, p = .046]. Intracaudate administration of the
highest dose of MPEP (10 μg/μL) did not alter cumulative locomotor activity (Figure 3C). An
ANOVA showed a significant effect of time only [F(14,84) = 57.50, p < .001], with no effect
of MPEP and no MPEP × time interaction.
Intra-mPFC administration of MPEP in the mPFC (Figures 1E and 1F) did not significantly
alter total ethanol (Figure 3D) or water responses (Table 3). Analysis of the pattern of response
across time showed a significant main effect of time [F(5,20) = 17.85, p < .001]. The main
effect of intra-mPFC MPEP dose and the interaction were not significant (Figure 3E). The
highest dose of MPEP (30 μg/μL) tested in the mPFC produced no effect on cumulative
locomotor activity (Figure 3F), with ANOVA confirming only a significant effect of time [F
(14,56) = 59.57, p < .001]. No significant main effect of MPEP dose or interaction was observed
on locomotor activity.
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Testing of mGluR5 Antagonist in the Nucleus Accumbens on Sucrose Self-Administration
and Motor Activity
Average baseline data (mean ± SEM) for the 2 days preceding the sham test of MPEP on
sucrose self-administration are shown in Table 1. Nucleus accumbens administration (Figures
1A and 1D) of MPEP did not alter sucrose self-administration (.4% w/v; Figure 4A). Water-
responding was also not altered by MPEP pretreatment (Table 3). Analysis of cumulative
sucrose responses across the 30-min session indicated a significant main effect of time [F(5,25)
= 31.94, p < .001] but no main effect of MPEP dose (Figure 4B). A significant interaction was
found [F(20,100) = 1.98, p = .01]; however, sucrose-reinforced responding after intra-
accumbens MPEP administration did not significantly differ from aCSF at any time point
throughout the session.
Intra-accumbens administration of the highest MPEP dose tested (30 μg) did not alter
spontaneous motor activity in sucrose-exposed rats (Figure 4C). Analysis of the cumulative
distance traveled across the 30-min session showed a significant main effect of time [F(14,84)
= 44.18, p < .001] but no main effect of MPEP dose or interaction.
Discussion
This study was designed to investigate functional involvement of nucleus accumbens mGluR5
and mGluR2/3 in ethanol reinforcement in the alcohol-preferring P-rat line, which is a
prominent genetic model of excessive alcohol-drinking (64). Accordingly, P-rats self-
administered relatively high levels of ethanol (range .74 g/kg–1.32 g/kg) during 30-min operant
sessions, for which we have shown results in blood ethanol levels of approximately 80 mg/dL
(57). Results showed that pharmacological inhibition of mGluR5 in the nucleus accumbens
produced a 70% reduction in ethanol self-administration in the absence of nonspecific effects
on motor activity. Functional specificity of mGluR5 was confirmed, because activation of
mGluR2/3 in the nucleus accumbens did not selectively alter ethanol self-administration.
Blockade of mGluR5 in two other brain regions (mPFC and dorsomedial caudate) produced
no effect on ethanol self-administration, indicating anatomical specificity of mGluR5 function
in this behavior. Furthermore, ethanol specificity was confirmed, because intra-accumbens
mGluR5 antagonism did not alter self-administration of another reinforcing solution (i.e.,
sucrose). These results indicate mGluR5 activity in the nucleus accumbens is required for the
full expression of ethanol's reinforcing effects in individuals with a genetic predisposition for
heavy alcohol-drinking.
Previous work has determined a role for mGluR5 in ethanol reinforcement as evidenced by
reductions in ethanol self-administration after systemic administration of mGluR5 antagonists
(48–51,56,71). This study shows that infusion of the mGluR5 antagonist MPEP (0 μg–10 μg)
in the nucleus accumbens reduces ethanol-reinforced responding. The mGluR5 antagonism,
or gene knockout, has been shown to potentiate ethanol's acute sedative-hypnotic effects and
produce motor impairments after moderate alcohol doses (72–74); thus, examination of the
temporal pattern of responding was critical for the interpretation of the total session reductions
in ethanol self-administration. Intra-accumbens mGluR5 antagonism produced a general
suppression of ethanol-reinforced responding throughout the 30-min self-administration
session, indicating that MPEP effects were independent of consumed ethanol. Furthermore,
the prolonged suppression of ethanol-reinforced responding across the 30-min session is
consistent with the time course of mGluR5 occupancy after systemic MPEP injection (i.e., full
receptor occupancy sustained for at least 1 hour (75). Finally, the reduction in ethanol self-
administration is likely not related to drug substitution, because mGluR5 antagonism itself
does not produce ethanol-like properties and does not alter the subjective properties of low
ethanol dose (76–78).
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The results of this study complement other evidence showing that glutamate transmission in
the nucleus accumbens regulates ethanol reinforcement. Microinjection of the competitive
NMDA receptor antagonist AP-5 into the nucleus accumbens of Wistar rats reduced ethanol-
reinforced responding (42). The present study extends this work by showing that inhibition of
mGluR5 but not mGluR2/3 activity specifically in the nucleus accumbens reduces the
maintenance of ethanol-reinforced responding in P-rats that were self-administering relatively
high doses of ethanol under control conditions (mean 1.04 g/kg/30-min session). Thus, it seems
that disrupting glutamate neurotransmission either through blockade of postsynaptic ionotropic
NMDA or metabotropic mGluR5 in the nucleus accumbens is sufficient to prevent the full
expression of ethanol's reinforcing properties.
mGluR5s are widely expressed throughout the striatum (44), with similar expression in the
nucleus accumbens and caudate putamen (76,79,80). However, infusion of MPEP in the
dorsomedial caudate, contrary to the nucleus accumbens infusion, had no effect on ethanol
self-administration. The dorsal striatum has been shown to regulate cocaine self-administration
by dopamine and AMPA/kainate receptors (81) and ethanol self-administration by NMDA
(NR2B) receptors (82). Furthermore, the dorsal striatum has been implicated in learning
stimulus-response relations associated with habit formation (83). Given that compulsive/
habitual drug use—a hallmark of drug addiction—can be regarded as maladaptive stimulus-
response relations, the dorsal striatum has become a region of significant interest in the drug
abuse field (84). Although the present findings suggest that mGluR5 within this region do not
modulate the maintenance of ethanol-reinforced responding, a partial trend was observed at
the highest dose of MPEP tested, suggesting that an extended dose range of MPEP or another
mGluR5 antagonist such as 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine might show
efficacy. It will also be both interesting and important for future work to determine whether
mGluR5 in the dorsal striatum regulate other aspects of ethanol-seeking behavior that rely on
conditioned reinforcement, such as cue-induced reinstatement.
Functional specificity of nucleus accumbens mGluR5 was further evaluated by examining the
effects of MPEP infusion in the mPFC on the maintenance of ethanol self-administration. The
mPFC was tested for several reasons. First, this brain region has been shown to modulate
ethanol self-administration (58,85,86), and low doses of ethanol increase extracellular
glutamate levels in the mPFC of alcohol-preferring Lewis rats (87). Second, mGluR5 regulate
firing rate of mPFC neurons (88), which is a neural correlate of reward prediction (89). Third,
the mPFC sends glutamatergic projections to the nucleus accumbens, and inactivation of the
mPFC reduces the firing rate of nucleus accumbens neurons in response to reward-predictive
cues (90). Thus, inhibition of postsynaptic mGluR5 in the mPFC might alter ethanol self-
administration via local mechanisms or by dampening mPFC glutamatergic inputs to the
nucleus accumbens. Results showed, however, that infusion of the mGluR5 antagonist MPEP
in the mPFC had no effect on ethanol self-administration. This was evident even though a
higher MPEP dose range was tested in the mPFC compared with the nucleus accumbens. These
findings suggest that mGluR5 in the mPFC are not involved in the regulation of the maintenance
of ethanol self-administration. However, because the mPFC regulates response to predictive
cues, mGluR5 in this brain region might influence behaviors that are regulated by associative
learning, such as cue-induced reinstatement of ethanol seeking.
Specificity of nucleus accumbens mGluR5 was further confirmed by testing the role of
mGluR2/3 in ethanol self-administration. Intra-accumbens mGluR2/3 activation reduced
ethanol self-administration. This was evident by a reduction in total session ethanol-reinforced
responding and a pattern of suppression similar to that observed after mGluR5 antagonism
(i.e., general suppression of responding throughout the session). These results are consistent
with evidence showing that intra-accumbens infusion of the mGlu2/3 agonist APDC reduced
ethanol-drinking in a 4-bottle home-cage procedure by C57Bl/6 J and DBA2/J mice (91).
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However, results from the present study showed that LY379268 also reduced spontaneous
motor activity, suggesting that reductions in ethanol-reinforced responding were likely due to
a motor impairment. This finding is consistent with the findings of a study by Backstrom and
Hyytia (92) in which a systemically administered mGluR2/3 agonist produced a significant
reduction in ethanol self-administration at a dose that was accompanied by a motor impairment
(but see [93]). Given that LY379268 decreased ethanol self-administration only at a dose that
produced nonspecific reductions in locomotor activity, these findings indicate that mGluR2/3
activation in the nucleus accumbens does not selectively modulate the maintenance of ethanol
self-administration. However, because systemically administered mGluR2/3 agonists exhibit
efficacy in other behavioral procedures, such as models of relapse, anxiety, and stress reactivity
during abstinence (93–95), future work might determine a more selective role of intra-
accumbens mGluR2/3 in these pathological behaviors.
To determine whether mGluR5 in the nucleus accumbens produces a reduction in the
maintenance of self-administration of a rewarding substance in general, intra-accumbens
mGluR5 antagonism was assessed in rats trained to self-administer sucrose versus water.
Baseline level of sucrose (.4% w/v) self-administration was similar to the baseline ethanol self-
administration, consistent with our previous findings (56,57). Accordingly, differences in self-
administration behavior between the sucrose and ethanol group cannot be attributed to
differential effects of the mGluR5 antagonist on response rate. Intra-accumbens antagonism
was without effect on sucrose self-administration, even as an mGluR5 antagonist dose range
higher than for ethanol self-administration was tested. This finding suggests specificity of the
effects of mGluR5 antagonism to ethanol reinforcement and also confirms the lack of
antagonist-induced nonspecific motor effects. Furthermore, the dissociation of mGluR5
involvement in ethanol versus sucrose reinforcement is similar to the findings of another study
in which motivation to self-administer ethanol but not sucrose was reduced after systemic
mGluR5 antagonism (57). Overall, some studies have shown reductions in food-reinforced
behavior after mGluR5 antagonism (96,97), whereas other studies have not (53,98,99).
However, the present results are consistent with another study that showed no change in sucrose
self-administration after intra-accumbens mGluR5 antagonism (100). Together, this data
pattern supports a role for intra-accumbens mGluR5 in the selective modulation of ethanol
self-administration.
One issue that should be discussed when considering mGlu receptor subtype specificity relates
to the selectivity of mGlu receptor compounds tested. Studies have emerged showing that the
mGluR5 antagonist MPEP modulates the activity of other receptor systems. For instance,
MPEP has been shown to blunt NMDA-evoked currents (101), inhibit the norepinephrine
transporter (102), and act as a positive allosteric modulator of mGlu4 receptors (103). The
mGluR2/3 agonist LY379268 has recently been shown to stimulate dopamine D2 receptors
(104). Moreover, MPEP infused in the nucleus accumbens inhibits intra-accumbens mGluR5
agonist-induced GABA release in the ventral pallidum (105). Because these receptor systems
have been shown to modulate ethanol self-administration or voluntary ethanol-drinking (29,
82,106–108), it is possible that mGluR5 inhibition in the nucleus accumbens reduced ethanol
self-administration via nonspecific pharmacological effects or regulation of associated neural
circuit(s).
In conclusion, there is growing interest in developing mGlu receptor compounds as
therapeutics for drug and alcohol use disorders (109), because these compounds have been
shown to reduce self-administration and relapse to drug-taking of several drugs of abuse (54,
110–112), including alcohol (48–51,56,57,71,91–93,113). The results of this study extend the
previous literature to show that inhibition of mGluR5 activity in the nucleus accumbens, a key
component of the brain's reward pathway, specifically reduces operant ethanol self-
administration. These data confirm the importance of mGluR5 activity in the nucleus
Besheer et al. Page 8













accumbens in regulating drug reinforcement and emphasize the potential therapeutic utility of
targeting this receptor system in individuals with genetic risk for excessive drinking.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Illustrations of cannulae and injector placements. Injector placements from individual rats with
accurate bilateral placements in the (A) nucleus accumbens, (C) dorsomedial caudate, and
(E) medial prefrontal cortex. Circles represent animals trained on ethanol self-administration
tested with 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP); squares represent
animals trained on ethanol self-administration tested with LY379268; and diamonds represent
animals trained on sucrose self-administration tested with MPEP. Representative
photomicrographs showing cannula (closed arrows) and injector (open arrows) tracks in
nucleus accumbens (B), dorsomedial caudate (D), and medial prefrontal cortex (F). ac, anterior
commissure; cc, corpus callosum. Figures A, C, and E published in The Rat Brain in Stereotaxic
Coordinates, 4th ed. (CD-ROM) by Paxinos and Watson, Copyright Elsevier (1998).
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Intra-accumbens metabotropic glutamate 5 (mGlu5) antagonism reduces ethanol self-
administration without affecting spontaneous motor activity. (A) Mean (± SEM) responses on
the ethanol (15% v/v) lever after intra-accumbens administration of the mGluR5 antagonist 2-
methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP) and a sham infusion (to left of axis
break). (B) Mean (± SEM) cumulative ethanol responses across the 30-min self-administration
session after intra-accumbens MPEP administration. (C) Mean (± SEM) cumulative distance
traveled (cm) during the 30-min locomotor assessment after intra-accumbens administration
of MPEP (10 μg). (D) Mean (± SEM) responses on the ethanol (15% v/v) lever after intra-
accumbens administration of the mGluR2/3 agonist LY379268 (LY) and a sham infusion (to
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left of axis break). (E) Mean (± SEM) cumulative ethanol responses across the 30-min self-
administration session after intra-accumbens LY administration. (F) Mean (± SEM)
cumulative distance traveled (cm) during the 30-min locomotor assessment after intra-
accumbens administration of LY (.17 μg). aCSF, artificial cerebrospinal fluid. *Significant
difference from vehicle (Tukey, p < .05).
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Intracaudate or medial prefrontal cortex (mPFC) antagonism of mGluR5 does not alter ethanol
self-administration or spontaneous motor activity. (A) Mean (± SEM) responses on the ethanol
(15% v/v) lever after intra-dorsomedial caudate putamen administration of the mGluR5
antagonist MPEP and a sham infusion (to left of axis break). (B) Mean (± SEM) cumulative
ethanol responses across the 30-min self-administration session after intracaudate MPEP
administration. (C) Mean (± SEM) cumulative distance traveled (cm) during the 30-min
locomotor assessment after intracaudate administration of MPEP (10 μg). (D) Mean (± SEM)
responses on the ethanol (15% v/v) lever after intra-mPFC administration of the mGluR5
antagonist MPEP and a sham infusion (to left of axis break). (E) Mean (± SEM) cumulative
ethanol responses across the 30-min self-administration session after intra-mPFC MPEP
administration. (F) Mean (± SEM) cumulative distance traveled (cm) during the 30 min
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locomotor assessment after intra-mPFC administration of MPEP (30 μg). Abbreviations as
Figures 1 and 2.
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Intra-accumbens mGluR5 antagonism does not alter sucrose self-administration or
spontaneous motor activity. (A) Mean (± SEM) responses on the sucrose (.4% w/v) lever after
intra-accumbens administration of the mGluR5 antagonist MPEP and a sham infusion (to left
of axis break). (B) Mean (± SEM) cumulative ethanol responses across the 30-min self-
administration session after intra-accumbens MPEP administration. (C) Mean (± SEM)
cumulative distance traveled (cm) during the 30-min locomotor assessment after intra-
accumbens administration of MPEP (10 μg). Abbreviations as Figures 1 and 2.
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Table 1




(g/kg)Ethanol Lever Water Lever
Ethanol Reinforcement
 Nucleus Accumbens (MPEP) 180.67 ± 44.90 20.33 ± 7.76 .96 ± .22
 Nucleus Accumbens (LY379268) 202.42 ± 40.38 6.00 ± 1.68 1.32 ± .29
 Dorsomedial Caudate (MPEP) 185.36 ± 27.93 23.86 ± 8.74 1.15 ± .18
 Medial Prefrontal Cortex (MPEP) 187.00 ± 12.46 23.40 ± 11.32 1.02 ± .08
Sucrose Reinforcement
 Nucleus Accumbens (MPEP) 171.93 ± 21.21 25.43 ± 7.83
mGlu, metabotropic glutamate; MPEP, 2-methyl-6-(phenylethynyl)pyridine hydrochloride.
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